NCT06539182 - DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

April 29, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

March 31, 2028

Conditions

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

DRUG

DZD8586

Daily oral dose of DZD8586 at 25 mg.

DRUG

DZD8586

Daily oral dose of DZD8586 at 50 mg.

DRUG

DZD8586

Daily oral dose of DZD8586 at 75 mg.

Trial Locations (17)

100053

RECRUITING

Research Site, Beijing

100191

RECRUITING

Research Site, Beijing

300020

RECRUITING

Research Site, Tianjin

300060

RECRUITING

Research Site, Tianjin

510280

RECRUITING

Research Site, Guangzhou

510515

RECRUITING

Research Site, Guangzhou

Unknown

RECRUITING

Research Site, Hefei

RECRUITING

Research Site, Zhengzhou

RECRUITING

Research Site, Wuhan

RECRUITING

First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing

RECRUITING

Research Site, Changchun

NOT_YET_RECRUITING

Research Site, Dalian

RECRUITING

Research Site, Shenyang

RECRUITING

Research Site, Jinan

RECRUITING

Research Site, Linyi

RECRUITING

Research Site, Shanghai

RECRUITING

Research Site, Taiyuan